Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jun 17, 2022
Date Accepted: Oct 28, 2022
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence with Inflammatory Bowel DiSease Therapy—ASSIST Study: A Randomized Controlled Trial
ABSTRACT
Background:
Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract often requiring long-term medical therapy. While adherence to IBD therapies is associated with improved clinical outcomes, overall adherence is poor with reports demonstrating adherence rates ranging from 40% to 80%. Consequently, there is a critical need to develop interventions that monitor adherence in-real time and identify reasons for non-adherence to support clinical teams in initiating effective interventions. Recently, electronic- and virtual-based platforms have been developed to routinely monitor adherence and guide appropriate interventions. A novel remote therapeutic monitoring (RTM) technology, the TapptTM digital health system, has been developed to monitor real-time medication adherence patterns through smart label technologies, capture patient reported outcomes (PROs) and barriers to care, and process patient data through algorithms that trigger personalized digital and human touchpoints between clinical visits. Such digital health solution enables care teams to proactively identify and mitigate nonadherence and worsening clinical outcomes.
Objective:
We propose a 12-month, multicenter, randomized, controlled trial to assess the effectiveness of TapptTM digital health system on adherence, clinical outcomes, and healthcare utilization among patients diagnosed with IBD starting a new oral or subcutaneous therapy.
Methods:
Specifically, we will (Aim 1) compare adherence as measured by the Medication Possession Ratio (MPR) in participants using the RTM compared to standard of care and (Aim 2) compare clinical outcomes and healthcare utilization in participants using the RTM compared to standard of care.
Results:
We anticipate starting recruitment in August 2022.
Conclusions:
Effective medication adherence monitoring and intervention programs need to be cost-efficient, pose little to no burden to the patient, be unobtrusive, record reliable data in real-time, and provide actionable insights to the healthcare team. We anticipate the TapptTM digital health system to improve the MPR, clinical outcomes, and healthcare utilization compared to standard of care. Clinical Trial: NCT05316584
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.